FDA 483 - Washington University School of Medicine - June 14, 2019

An FDA inspection of Washington University School of Medicine, a PET Drug Manufacturer in St. Louis, revealed significant deficiencies in their manufacturing operations. The firm failed to establish adequate process controls, validate methods and processes, manage facility changes, and ensure proper laboratory and production oversight. These issues indicate a broad lack of adherence to good manufacturing practices, potentially impacting product quality and safety.